Catalyst Pharmaceuticals Inc (CPRX)
21.12
-0.03
(-0.14%)
USD |
NASDAQ |
Nov 21, 16:00
21.12
0.00 (0.00%)
After-Hours: 20:00
Catalyst Pharmaceuticals Revenue (Quarterly): 128.70M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 128.70M |
| June 30, 2024 | 122.71M |
| March 31, 2024 | 98.51M |
| December 31, 2023 | 110.57M |
| September 30, 2023 | 102.69M |
| June 30, 2023 | 99.58M |
| March 31, 2023 | 85.37M |
| December 31, 2022 | 60.76M |
| September 30, 2022 | 57.24M |
| June 30, 2022 | 53.11M |
| March 31, 2022 | 43.09M |
| December 31, 2021 | 38.31M |
| September 30, 2021 | 35.95M |
| June 30, 2021 | 36.36M |
| March 31, 2021 | 30.20M |
| December 31, 2020 | 31.02M |
| September 30, 2020 | 29.32M |
| June 30, 2020 | 29.60M |
| March 31, 2020 | 29.14M |
| December 31, 2019 | 30.12M |
| September 30, 2019 | 30.90M |
| June 30, 2019 | 28.84M |
| March 31, 2019 | 12.45M |
| December 31, 2018 | 0.50M |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
29.14M
Minimum
Mar 2020
128.70M
Maximum
Sep 2024
62.62M
Average
48.10M
Median
Revenue (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 182.55M |
| Vertex Pharmaceuticals Inc | 2.772B |
| Sarepta Therapeutics Inc | 467.17M |
| ADMA Biologics Inc | 119.84M |
| BioVie Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 43.88M |
| Total Expenses (Quarterly) | 77.79M |
| EPS Diluted (Quarterly) | 0.35 |
| Enterprise Value | 2.077B |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | 34.10% |
| Earnings Yield | 5.59% |
| Operating Earnings Yield | 6.76% |
| Normalized Earnings Yield | 5.599 |